Zoetis Reports First Quarter 2016 Results
-
For First Quarter 2016, Zoetis Delivers 12% Operational Growth in Revenue and 28% Operational Growth in Adjusted Net Income,
Excluding Foreign Exchange
- Reported First Quarter 2016 Revenue of $1.2 Billion and Reported Net Income of $204 Million,
or $0.41 per Diluted Share
- First Quarter 2016 Adjusted Net Income of $239 Million, or Adjusted Diluted EPS of $0.48
- Updates Full Year 2016 Revenue Guidance to $4.775 - $4.875 Billion and Adjusted Diluted EPS to
$1.83 - $1.90
- Updates Full Year 2017 Revenue Guidance to $5.075 - $5.275 Billion and Adjusted Diluted EPS to
$2.24 - $2.38
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2016 and updated its
guidance for full year 2016 and full year 2017.
The company reported revenue of $1.2 billion for the first quarter of 2016, an increase of 5% compared with the first quarter of
2015. Revenue reflected an operational1 increase of 12%, excluding the impact of foreign currency.
Net income for the first quarter of 2016 was $204 million, or $0.41 per diluted share, an increase of 24%, compared with the
first quarter of 2015. Adjusted net income2 for the first quarter of 2016 was $239 million, or $0.48 per diluted share,
an increase of 15% and 17%, respectively. Adjusted net income for the first quarter of 2016 excludes the net impact of $35 million,
or $0.07 per diluted share, for purchase accounting adjustments, acquisition-related costs and certain significant items. On an
operational basis, adjusted net income for the first quarter of 2016 increased 28%, with foreign currency having a negative impact
of 13 percentage points.
Due to accounting calendars, the first quarter of 2016 includes six additional calendar days compared with the first quarter of
2015, resulting in higher sales, costs and expenses. The company estimates the impact of the additional days to be approximately 6
percentage points of operational growth.
EXECUTIVE COMMENTARY
“Zoetis delivered solid operational revenue growth in the first quarter, with the full benefit of our diverse portfolio and
business model on display. The growth in companion animal products drove our performance, while we experienced softer growth in our
livestock products and a negative impact from the product rationalization and market changes in Venezuela and India that we
communicated last year,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “Our core capabilities in direct customer
interaction, R&D and manufacturing keep us well-positioned to lead the animal health industry.”
“The execution of our operational efficiency program continues to help us grow adjusted net income faster than sales, and we are
on track to exceed our initial targets,” said Alaix. “With improved foreign exchange rates and the positive momentum of the
business, we are increasing our adjusted diluted EPS guidance for 2016 and 2017.”
Paul Herendeen, Executive Vice President and Chief Financial Officer of Zoetis, said, “There was a lot going on in our results
for the first quarter including having six extra days due to our financial calendar and seeing the impact of changes we are making
to rationalize our product portfolio and geographic footprint. Looking through the noise, we posted another solid quarter. Foreign
exchange rates continued to constrain our reported revenue growth -- reducing reported revenue by 700 basis points compared with
the prior year quarter -- but we expect a more muted impact over the balance of the year based on current rates. We are off to a
great start in 2016 and are confident that we will enter 2017 with the right product portfolio, focused in the right countries and
with the right level of resources to deliver revenue growth over the long term that is equal to or faster than the markets in which
we compete.”
QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its business across two regional operating segments: the United States (U.S.) and International.
Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local
trends and customer needs. These segment results reflect the six additional calendar days mentioned above. In the first quarter of
2016:
- Revenue in the U.S. segment was $582 million, an increase of 12% compared with the first
quarter of 2015. Sales of companion animal products grew 32%, due primarily to increased sales of APOQUEL®, initial
sales of other products into expanded distribution relationships, and the addition of products acquired from Abbott Animal
Health. Livestock revenue declined 4% due to decreased sales of cattle and swine products. In cattle, our premium products were
impacted by mild winter weather that resulted in decreased disease risk and incidence, while certain swine products were impacted
by increased competition. Poultry products partially offset these declines as customers rotated onto our medicated feed additive
products.
- Revenue in the International segment was $567 million, an increase of 13% operationally
compared with the first quarter of 2015. Sales of livestock products grew 9% operationally, driven by the addition of revenue,
primarily in Chile and Norway, from recently acquired PHARMAQ. Additionally, sales of cattle products grew in France and Brazil.
Growth in France was due to lower than normal sales in the year-ago quarter resulting from implementation of new legislation,
while growth in Brazil was driven by price increases and favorable market conditions. Livestock growth, however, was partially
offset by business reductions in Venezuela and India and product rationalization. Sales of companion animal products increased
23% operationally, driven in part from increased sales of APOQUEL in existing markets – primarily the United Kingdom, Spain, and
Germany – and new markets – France and Australia. Growth also benefited from performance in China and Japan. In China, growth was
driven by demand for our vaccines portfolio, while Japan’s growth was driven by competitor supply issues and timing of customer
purchases. Additionally, sales of products acquired from Abbott Animal Health benefited companion animal growth.
Zoetis continues to drive demand and strengthen its diverse portfolio of products through lifecycle innovations, strong customer
relationships and access to new markets and technologies. The company is focused on improving the performance and delivery of its
current product lines; expanding product indications across species; pursuing approvals in new geographies; and developing
innovative medicines, treatments and solutions for emerging diseases and unmet customer needs. Some recent highlights include:
- Zoetis expanded its line of livestock vaccines in China in the first quarter. In March, the company
received approval for RUI LAN WEN™, the first combination vaccine approved in China to help protect pigs against classical
swine fever (CSF) and porcine reproductive and respiratory syndrome (PRRS) prevalent in China. This is the second vaccine
resulting from the Zoetis Jilin Guoyuan joint venture in China. Zoetis also gained approval in China for
POULVAC® MAREK CVI+HVT, a vaccine to help prevent Marek’s disease in poultry.
- The company has received licenses from the USDA for a new VANGUARD® B
Oral vaccine and three new VANGUARD® Intranasal Rapid Resp vaccines. Zoetis is now the
first and only manufacturer to offer oral, intranasal and injectable options for vaccinating dogs against Bordetella
bronchiseptica, which is considered a common pathogen in canine infectious respiratory disease.
- At the end of the first quarter, Zoetis was granted a conditional license from the U.S. Department of
Agriculture (USDA) for Avian Influenza Vaccine, H5N1 Subtype, Killed Virus3. The vaccine is intended
for use in chickens as an aid in the prevention of disease caused by avian influenza virus H5N1, a highly pathogenic disease that
caused the largest animal health emergency in U.S. history during the spring and summer of 2015, according to the USDA. Zoetis is
participating in a competitive bidding process to supply the USDA with this vaccine for the National Veterinary Stockpile should
they decide a vaccination strategy is needed.
Zoetis continues to expand major products into new markets.
- Following an approval last year in the EU markets, Zoetis received approval for SIMPARICA™
(sarolaner) in the U.S. and Canada and SIMPARIC™ in Brazil; this is a new oral parasiticide for dogs that enables the
company to compete in the fastest growing segment of the approximately $3 billion global market of flea and tick products.
- With the approval of APOQUEL in Japan in the first quarter, the product is now approved in all major
markets. APOQUEL® (oclacitinib tablet) is a novel Janus Kinase inhibitor for the control of pruritus, or itching,
associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age.
- Zoetis also received a conditional license in Canada for Canine Atopic Dermatitis
Immunotherapeutic3, a first-of-its-kind antibody therapy that targets and neutralizes interleukin-31
(IL-31) to help reduce clinical signs associated with atopic dermatitis in dogs.
FINANCIAL GUIDANCE
Zoetis' guidance for the full year 2016 and the full year 2017 continues to reflect the company’s confidence in its diverse
portfolio, the strength of its business model, and the stability and predictability of the animal health industry.
Zoetis has updated elements of its guidance today to reflect foreign exchange rates as of April and current views of its
operations. Considering these factors, the company’s guidance for the full year 2016 and the full year 2017 is the following:
Full Year 2016:
- Revenue of between $4.775 billion to $4.875 billion
- Reported diluted EPS for the full year of between $1.41 to $1.56 per share
- Adjusted diluted EPS for the full year between $1.83 to $1.90 per share
Full Year 2017 (updated solely for foreign exchange rates):
- Revenue of between $5.075 billion to $5.275 billion
- Reported diluted EPS for the full year of between $2.01 to $2.19 per share
- Adjusted diluted EPS for the full year between $2.24 to $2.38 per share
Additional guidance on other items such as expenses and tax rate is included in the financial tables and will be discussed on
the company's conference call this morning.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (EDT) today, during which company executives will review first
quarter 2016 results, discuss 2016 financial guidance and respond to questions from financial analysts. Investors and the public
may access the live webcast by visiting the Zoetis website at http://www.zoetis.com/events-and-presentations. A replay of the webcast will be
archived and made available on May 4, 2016.
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting
its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops,
manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by
a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals
with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with
approximately 9,000 employees. For more information, visit www.zoetis.com.
1 Operational revenue growth is defined as revenue growth excluding the impact of foreign
exchange.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial
measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase
accounting adjustments, acquisition-related costs and certain significant items.
3This product license is conditional. Efficacy and potency tests are in progress.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements,
which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance,
future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and
tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements
are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or
more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results
may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date
on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise. A further list and description of risks, uncertainties and other
matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections
thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online
at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as
adjusted net income and adjusted diluted earnings per share, to assess and analyze our operational results and trends and to make
financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide
greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not
be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and
should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP
information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in
the tables accompanying this press release and are posted on our website at www.zoetis.com.
Internet Posting of Information: We routinely post information that may be important to
investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to
consult our website regularly and to follow us on Facebook and Twitter for important information about us.
|
|
|
ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)
(UNAUDITED)
(millions of dollars, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
|
|
|
2016 |
|
2015 |
|
% Change |
| Revenue |
|
|
$ |
1,162 |
|
|
$ |
1,102 |
|
|
5 |
|
| Costs and expenses: |
|
|
|
|
|
|
|
|
| Cost of sales(b) |
|
|
389 |
|
|
394 |
|
|
(1 |
) |
| Selling, general and administrative expenses(b) |
|
|
315 |
|
|
354 |
|
|
(11 |
) |
| Research and development expenses(b) |
|
|
90 |
|
|
80 |
|
|
13 |
|
| Amortization of intangible assets(c) |
|
|
21 |
|
|
15 |
|
|
40 |
|
| Restructuring charges and certain acquisition-related costs |
|
|
2 |
|
|
1 |
|
|
100 |
|
| Interest expense |
|
|
43 |
|
|
28 |
|
|
54 |
|
| Other (income)/deductions–net |
|
|
(30 |
) |
|
— |
|
|
*
|
|
| Income before provision for taxes on income |
|
|
332 |
|
|
230 |
|
|
44 |
|
| Provision for taxes on income |
|
|
128 |
|
|
65 |
|
|
97 |
|
| Net income before allocation to noncontrolling interests |
|
|
204 |
|
|
165 |
|
|
24 |
|
| Less: Net income attributable to noncontrolling interests |
|
|
— |
|
|
— |
|
|
— |
|
| Net income attributable to Zoetis |
|
|
$ |
204 |
|
|
$ |
165 |
|
|
24 |
|
|
|
|
|
|
|
|
|
|
| Earnings per share—basic |
|
|
$ |
0.41 |
|
|
$ |
0.33 |
|
|
24 |
|
|
|
|
|
|
|
|
|
|
| Earnings per share—diluted |
|
|
$ |
0.41 |
|
|
$ |
0.33 |
|
|
24 |
|
|
|
|
|
|
|
|
|
|
| Weighted-average shares used to calculate earnings per share (in thousands) |
|
|
|
|
|
|
|
|
| Basic |
|
|
497,399 |
|
|
501,146 |
|
|
|
|
| Diluted |
|
|
499,539 |
|
|
503,224 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * Calculation not meaningful. |
| |
| (a) |
|
The condensed consolidated statements of income present the three months ended April
3, 2016, and March 29, 2015. Subsidiaries operating outside the United States are included for the three months ended February
28, 2016 and February 22, 2015. |
|
|
|
| (b) |
|
Exclusive of amortization of intangible assets, except as discussed in footnote (c)
below. |
|
|
|
| (c) |
|
Amortization expense related to finite-lived acquired intangible assets that
contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property
is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization
expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling,
general and administrative expenses or Research and development expenses, as appropriate. |
| |
| Certain amounts and percentages may reflect rounding adjustments. |
| |
| |
|
|
|
|
|
ZOETIS INC.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars, except per share data)
|
|
|
|
|
|
|
|
Quarter ended April 3, 2016 |
|
|
|
GAAP
Reported(a)
|
|
Purchase
Accounting
Adjustments
|
|
Acquisition-
Related
Costs(1)
|
|
Certain
Significant
Items(2)
|
|
Non-GAAP
Adjusted(b)
|
| Revenue |
|
|
$ |
1,162 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,162 |
| Cost of sales(c) |
|
|
389 |
|
|
(7 |
) |
|
— |
|
|
(4 |
) |
|
378 |
| Gross profit |
|
|
773 |
|
|
7 |
|
|
— |
|
|
4 |
|
|
784 |
| Selling, general and administrative expenses(c) |
|
|
315 |
|
|
(1 |
) |
|
— |
|
|
(14 |
) |
|
300 |
| Research and development expenses(c) |
|
|
90 |
|
|
(1 |
) |
|
— |
|
|
— |
|
|
89 |
| Amortization of intangible assets(d) |
|
|
21 |
|
|
(17 |
) |
|
— |
|
|
— |
|
|
4 |
| Restructuring charges and certain acquisition-related costs |
|
|
2 |
|
|
— |
|
|
— |
|
|
|
(2 |
) |
|
— |
| Interest expense |
|
|
43 |
|
|
— |
|
|
— |
|
|
— |
|
|
43 |
| Other (income)/deductions–net |
|
|
(30 |
) |
|
— |
|
|
(1 |
) |
|
33 |
|
|
2 |
| Income before provision for taxes on income |
|
|
332 |
|
|
26 |
|
|
1 |
|
|
(13 |
) |
|
346 |
| Provision for taxes on income |
|
|
128 |
|
|
17 |
|
|
(2 |
) |
|
(36 |
) |
|
107 |
| Net income attributable to Zoetis |
|
|
204 |
|
|
9 |
|
|
3 |
|
|
23 |
|
|
239 |
| Earnings per common share attributable to Zoetis–diluted(e) |
|
|
0.41 |
|
|
0.02 |
|
|
0.01 |
|
|
0.04 |
|
|
0.48 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter ended March 29, 2015 |
|
|
|
GAAP
Reported(a)
|
|
Purchase
Accounting
Adjustments
|
|
Acquisition-
Related
Costs(1)
|
|
Certain
Significant
Items(2)
|
|
Non-GAAP
Adjusted(b)
|
| Revenue |
|
|
$ |
1,102 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
1,102 |
| Cost of sales(c) |
|
|
394 |
|
|
(2 |
) |
|
— |
|
|
(7 |
) |
|
385 |
| Gross profit |
|
|
708 |
|
|
2 |
|
|
— |
|
|
7 |
|
|
717 |
| Selling, general and administrative expenses(c) |
|
|
354 |
|
|
— |
|
|
— |
|
|
(34 |
) |
|
320 |
| Research and development expenses(c) |
|
|
80 |
|
|
— |
|
|
— |
|
|
— |
|
|
80 |
| Amortization of intangible assets(d) |
|
|
15 |
|
|
(11 |
) |
|
— |
|
|
— |
|
|
4 |
| Restructuring charges and certain acquisition-related costs |
|
|
1 |
|
|
— |
|
|
(1 |
) |
|
— |
|
|
— |
| Interest expense |
|
|
28 |
|
|
— |
|
|
— |
|
|
— |
|
|
28 |
| Other (income)/deductions–net |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
| Income before provision for taxes on income |
|
|
230 |
|
|
13 |
|
|
1 |
|
|
41 |
|
|
285 |
| Provision for taxes on income |
|
|
65 |
|
|
7 |
|
|
(2 |
) |
|
8 |
|
|
78 |
| Net income attributable to Zoetis |
|
|
165 |
|
|
6 |
|
|
3 |
|
|
33 |
|
|
207 |
| Earnings per common share attributable to Zoetis–diluted(e) |
|
|
0.33 |
|
|
0.01 |
|
|
0.01 |
|
|
0.06 |
|
|
0.41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (a) |
|
The condensed consolidated statements of income present the three months ended April
3, 2016, and March 29, 2015. Subsidiaries operating outside the United States are included for the three months ended February
28, 2016, and February 22, 2015. |
|
|
|
| (b) |
|
Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are
not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the
importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its
components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by
U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP
adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and
diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and
its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how
management assesses performance. |
|
|
|
| (c) |
|
Exclusive of amortization of intangible assets, except as discussed in footnote (d)
below. |
|
|
|
| (d) |
|
Amortization expense related to finite-lived acquired intangible assets that
contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property
is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization
expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling,
general and administrative expenses or Research and development expenses, as appropriate. |
|
|
|
| (e) |
|
EPS amounts may not add due to rounding. |
|
|
|
| See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted
Information for notes (1) and (2). |
| |
| Certain amounts may reflect rounding adjustments. |
| |
| |
|
|
|
|
|
ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
|
|
|
|
|
|
(1) Acquisition-related costs include the following:
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
|
|
2016 |
|
2015 |
| Integration costs(a) |
|
|
$ |
— |
|
|
$ |
1 |
|
| Other(b) |
|
|
1 |
|
|
— |
|
| Total acquisition-related costs—pre-tax |
|
|
1 |
|
|
1 |
|
| Income taxes(c) |
|
|
(2 |
) |
|
(2 |
) |
| Total acquisition-related costs—net of tax |
|
|
$ |
3 |
|
|
$ |
3 |
|
|
|
|
|
|
|
|
|
|
|
| (a) |
|
Integration costs represent external, incremental costs directly related to
integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.
Included in Restructuring charges and certain acquisition-related costs. |
|
|
|
| (b) |
|
Included in Other (income)/deductions—net. |
|
|
|
| (c) |
|
Included in Provision for taxes on income. Income taxes include the tax effect of the
associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that
jurisdiction's applicable tax rate, as well as a tax charge related to the acquisition of certain assets of Abbott Animal
Health. |
|
|
|
| Certain amounts may reflect rounding adjustments. |
|
|
|
| |
|
(2) Certain significant items include the following:
|
|
|
|
|
|
|
|
First Quarter |
|
|
|
2016 |
|
|
2015 |
| Operational efficiency initiative(a) |
|
|
$ |
(28 |
) |
|
|
$ |
10 |
| Supply network strategy(b) |
|
|
3 |
|
|
|
5 |
| Stand-up costs(c) |
|
|
12 |
|
|
|
23 |
| Other(d) |
|
|
— |
|
|
|
3 |
| Total certain significant items—pre-tax |
|
|
(13 |
) |
|
|
41 |
| Income taxes(e) |
|
|
(36 |
) |
|
|
8 |
| Total certain significant items—net of tax |
|
|
$ |
23 |
|
|
|
$ |
33 |
|
|
|
|
|
|
|
|
|
|
| (a) |
|
For the three months ended April 3, 2016, comprises restructuring charges of $2
million related to employee termination costs ($1 million) and exit costs ($1 million), included in Restructuring charges and
certain acquisition-related costs, consulting fees of $3 million, included in Selling, general and administrative expenses, and
a $33 million gain related to the sale of certain manufacturing sites and products (gross proceeds received were $75 million),
included in Other (income)/deductions—net. For the three months ended March 29, 2015, represents consulting fees included in
Selling, general and administrative expenses. |
|
|
|
| (b) |
|
For the three months ended April 3, 2016, comprises accelerated depreciation charges
of $1 million and consulting fees of $2 million, included in Cost of sales. For the three months ended March 29, 2015,
represents consulting fees included in Cost of sales. |
|
|
|
| (c) |
|
Represents certain nonrecurring costs related to becoming an independent public
company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of
standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs. Included in
Cost of sales ($1 million and $2 million) and Selling, general and administrative expenses ($11 million and $21 million) for
the three months ended April 3, 2016, and March 29, 2015, respectively. |
|
|
|
| (d) |
|
For the three months ended March 29, 2015, represents charges due to unusual
investor-related activities in Selling, general and administrative expenses. |
|
|
|
| (e) |
|
Included in Provision for taxes on income. Income taxes include the tax effect of the
associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that
jurisdiction's applicable tax rate. The three months ended April 3, 2016, also includes a net tax charge of approximately $35
million related to the impact of the European Commission’s negative decision on the excess profits rulings in Belgium. The net
charge of approximately $35 million relates to the recovery of prior tax benefits for the periods 2013 through 2015 offset by
the revaluation of the company’s deferred tax assets and liabilities using the rates expected to be in place at the time of the
reversal. This net charge does not include any benefits associated with a successful appeal of the decision, nor does it
reflect guidance we expect to receive from the Belgian government on the methodology and timing of the recovery of prior tax
benefits. |
|
|
|
| Certain amounts may reflect rounding adjustments. |
| |
| |
| |
|
ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME (a)
(UNAUDITED)
(millions of dollars)
|
| |
|
|
|
First Quarter |
|
|
% Change |
|
|
|
2016 |
|
|
2015 |
|
|
Total |
|
|
Foreign
Exchange
|
|
|
Operational |
| Adjusted cost of sales |
|
|
$ |
378 |
|
|
|
$ |
385 |
|
|
|
(2 |
)% |
|
|
(5 |
)% |
|
|
3 |
% |
| as a percent of revenue |
|
|
32.5 |
% |
|
|
34.9 |
% |
|
|
NA |
|
|
NA |
|
|
NA |
| Adjusted SG&A expenses |
|
|
300 |
|
|
|
320 |
|
|
|
(6 |
)% |
|
|
(5 |
)% |
|
|
(1 |
)% |
| Adjusted R&D expenses |
|
|
89 |
|
|
|
80 |
|
|
|
11 |
% |
|
|
(4 |
)% |
|
|
15 |
% |
| Adjusted net income attributable to Zoetis |
|
|
239 |
|
|
|
207 |
|
|
|
15 |
% |
|
|
(13 |
)% |
|
|
28 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (a) |
|
Adjusted cost of sales, adjusted selling, general, and administrative (SG&A)
expenses, adjusted research and development (R&D) expenses, and adjusted net income attributable to Zoetis are defined as
the corresponding reported U.S. generally accepted accounting principles (GAAP) income statement line items excluding purchase
accounting adjustments, acquisition-related costs, and certain significant items. Reconciliations of certain reported to
adjusted information for the three months ended April 3, 2016, and March 29, 2015, are provided in the materials accompanying
this report. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the
corresponding U.S. GAAP line items. |
| |
|
|
|
|
|
|
|
|
|
|
ZOETIS INC.
2016 GUIDANCE
|
| |
| |
|
Selected Line Items
(millions of dollars, except per share amounts)
|
|
|
Full Year 2016 |
| Revenue |
|
|
$4,775 to $4,875 |
| Operational growth(a) |
|
|
3% to 5% |
| Adjusted cost of sales as a percentage of revenue(b) |
|
|
33% to 34% |
| Adjusted SG&A expenses(b) |
|
|
$1,290 to $1,330 |
| Adjusted R&D expenses(b) |
|
|
$360 to $380 |
| Adjusted interest expense and other
(income)/deductions(b) |
|
|
Approximately $170 |
| Adjusted EBIT margin(b) |
|
|
Approximately 31% |
| Effective tax rate on adjusted income(b) |
|
|
Approximately 32% |
| Adjusted diluted EPS(b) |
|
|
$1.83 to $1.90 |
| Adjusted net income(b) |
|
|
$915 to $950 |
| Operational growth(a) |
|
|
9% to 13% |
| Certain significant items(c) and acquisition-related
costs |
|
|
$70 to $120 |
| Reported diluted EPS |
|
|
$1.41 to $1.56 |
| |
| A reconciliation of 2016 adjusted net income and adjusted diluted EPS guidance to
2016 reported net income attributable to Zoetis and reported diluted EPS attributable to Zoetis common shareholders guidance
follows: |
| |
| |
|
|
|
|
Full-Year 2016 Guidance |
| (millions of dollars, except per share amounts) |
|
Net Income |
|
Diluted EPS |
| Adjusted net income/diluted EPS(b) guidance |
|
~$915 - $950 |
|
~$1.83 - $1.90 |
| Purchase accounting adjustments |
|
~(65) |
|
~(0.13) |
| Certain significant items(c) and acquisition-related
costs |
|
~(105 - 145) |
|
~(0.21 - 0.29) |
| Reported net income attributable to Zoetis/diluted EPS guidance |
|
~$705 - $780 |
|
~$1.41 - $1.56 |
|
|
|
|
|
| (a) |
|
Operational growth excludes the impact of foreign exchange. |
|
|
|
| (b) |
|
Adjusted net income and its components and adjusted diluted EPS are defined as
reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding
purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted
selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, adjusted
interest expense and adjusted other (income)/deductions are income statement line items prepared on the same basis, and,
therefore, components of the overall adjusted income measure. Adjusted earnings before interest and taxes (EBIT) is defined as
reported EBIT excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Despite the
importance of these measures to management in goal setting and performance measurement, adjusted net income and its components
and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and,
therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and
its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable
to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are
presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its
components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its
components and diluted EPS. |
|
|
|
| (c) |
|
Primarily includes certain nonrecurring costs related to restructuring, net gains on
sales of assets, and other charges for the operational efficiency initiative and supply network strategy, becoming an
independent public company, such as new branding (including changes to the manufacturing process for required new packaging),
the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment
costs. |
| |
|
|
|
|
|
|
|
|
|
ZOETIS INC.
2017 GUIDANCE
|
| |
| |
|
|
|
Selected Line Items
(millions of dollars, except per share amounts)
|
|
Full Year 2017 |
| Revenue |
|
$5,075 to $5,275 |
| Operational growth(a) |
|
5% to 9% |
| Adjusted cost of sales as a percentage of revenue(b) |
|
32% to 33% |
| Adjusted SG&A expenses(b) |
|
$1,250 to $1,340 |
| Adjusted R&D expenses(b) |
|
$360 to $380 |
| Adjusted interest expense and other
(income)/deductions(b) |
|
Approximately $150 |
| Adjusted EBIT margin(b) |
|
Approximately 34% |
| Effective tax rate on adjusted income(b) |
|
Approximately 30% |
| Adjusted diluted EPS(b) |
|
$2.24 to $2.38 |
| Adjusted net income(b) |
|
$1,120 to $1,190 |
| Operational growth(a) |
|
20% to 28% |
| Certain significant items(c) and acquisition-related
costs |
|
$50 to $80 |
| Reported diluted EPS |
|
$2.01 to $2.19 |
|
|
|
| |
| A reconciliation of 2017 adjusted net income and adjusted diluted EPS guidance to
2017 reported net income attributable to Zoetis and reported diluted EPS attributable to Zoetis common shareholders guidance
follows: |
| |
| |
|
|
|
|
Full-Year 2017 Guidance |
| (millions of dollars, except per share amounts) |
|
Net Income |
|
Diluted EPS |
| Adjusted net income/diluted EPS(b) guidance |
|
~$1,120 - $1,190 |
|
~$2.24 - $2.38 |
| Purchase accounting adjustments |
|
~(60) |
|
~(0.12) |
| Certain significant items(c) and acquisition-related
costs |
|
~(35 - 55) |
|
~(0.07 - 0.11) |
| Reported net income attributable to Zoetis/diluted EPS guidance |
|
~$1,005 - $1,095 |
|
~$2.01 - $2.19 |
|
|
|
|
|
| (a) |
|
Operational growth excludes the impact of foreign exchange. |
|
|
|
| (b) |
|
Adjusted net income and its components and adjusted diluted EPS are defined as
reported U.S. generally accepted accounting principles (GAAP) net income and its components and reported diluted EPS excluding
purchase accounting adjustments, acquisition-related costs and certain significant items. Adjusted cost of sales, adjusted
selling, general and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, adjusted
interest expense, adjusted other (income)/deductions are income statement line items prepared on the same basis, and,
therefore, components of the overall adjusted income measure. Adjusted earnings before interest and taxes (EBIT) is defined as
reported EBIT excluding purchase accounting adjustments, acquisition-related costs and certain significant items. Despite the
importance of these measures to management in goal setting and performance measurement, adjusted net income and its components
and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and,
therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and
its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable
to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are
presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its
components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its
components and diluted EPS. |
|
|
|
| (c) |
|
Primarily includes certain nonrecurring costs related to restructuring, net gains on
sales of assets, and other charges for the operational efficiency initiative and supply network strategy, becoming an
independent public company, such as new branding (including changes to the manufacturing process for required new packaging),
the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment
costs. |
| |
|
|
|
|
|
| |
|
ZOETIS INC.
CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES
(UNAUDITED)
(millions of dollars)
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
|
% Change |
|
|
|
2016 |
|
|
2015 |
|
|
Total |
|
|
Foreign
Exchange
|
|
|
Operational |
| Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Livestock |
|
|
$ |
683 |
|
|
|
$ |
715 |
|
|
|
(4 |
)% |
|
|
(8 |
)% |
|
|
4 |
% |
| Companion Animal |
|
|
466 |
|
|
|
377 |
|
|
|
24 |
% |
|
|
(5 |
)% |
|
|
29 |
% |
| Contract Manufacturing |
|
|
13 |
|
|
|
10 |
|
|
|
30 |
% |
|
|
(9 |
)% |
|
|
39 |
% |
| Total Revenue |
|
|
$ |
1,162 |
|
|
|
$ |
1,102 |
|
|
|
5 |
% |
|
|
(7 |
)% |
|
|
12 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| U.S. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Livestock |
|
|
$ |
288 |
|
|
|
$ |
299 |
|
|
|
(4 |
)% |
|
|
— |
% |
|
|
(4 |
)% |
| Companion Animal |
|
|
294 |
|
|
|
222 |
|
|
|
32 |
% |
|
|
— |
% |
|
|
32 |
% |
| Total U.S. Revenue |
|
|
$ |
582 |
|
|
|
$ |
521 |
|
|
|
12 |
% |
|
|
— |
% |
|
|
12 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| International |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Livestock |
|
|
$ |
395 |
|
|
|
$ |
416 |
|
|
|
(5 |
)% |
|
|
(14 |
)% |
|
|
9 |
% |
| Companion Animal |
|
|
172 |
|
|
|
155 |
|
|
|
11 |
% |
|
|
(12 |
)% |
|
|
23 |
% |
| Total International Revenue |
|
|
$ |
567 |
|
|
|
$ |
571 |
|
|
|
(1 |
)% |
|
|
(14 |
)% |
|
|
13 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Livestock: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cattle |
|
|
$ |
377 |
|
|
|
$ |
397 |
|
|
|
(5 |
)% |
|
|
(8 |
)% |
|
|
3 |
% |
| Swine |
|
|
146 |
|
|
|
170 |
|
|
|
(14 |
)% |
|
|
(7 |
)% |
|
|
(7 |
)% |
| Poultry |
|
|
122 |
|
|
|
129 |
|
|
|
(5 |
)% |
|
|
(7 |
)% |
|
|
2 |
% |
| Fish |
|
|
17 |
|
|
|
— |
|
|
|
* |
|
|
* |
|
|
* |
| Other |
|
|
21 |
|
|
|
19 |
|
|
|
11 |
% |
|
|
(8 |
)% |
|
|
19 |
% |
| Total Livestock Revenue |
|
|
$ |
683 |
|
|
|
$ |
715 |
|
|
|
(4 |
)% |
|
|
(8 |
)% |
|
|
4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companion Animal: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Horses |
|
|
$ |
39 |
|
|
|
$ |
40 |
|
|
|
(3 |
)% |
|
|
(5 |
)% |
|
|
2 |
% |
| Dogs and Cats |
|
|
427 |
|
|
|
337 |
|
|
|
27 |
% |
|
|
(5 |
)% |
|
|
32 |
% |
| Total Companion Animal Revenue |
|
|
$ |
466 |
|
|
|
$ |
377 |
|
|
|
24 |
% |
|
|
(5 |
)% |
|
|
29 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * Calculation not meaningful. |
| |
| (a) |
|
For a description of each segment, see Note 19A to Zoetis' consolidated financial
statements included in Zoetis' Form 10-K for the year ended December 31, 2015. |
|
|
|
| Certain amounts and percentages may reflect rounding adjustments. |
| |
| |
|
|
|
|
|
|
|
|
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
|
% Change |
|
|
|
2016 |
|
|
2015 |
|
|
Total |
|
|
Foreign
Exchange
|
|
|
Operational |
| Total International |
|
|
$ |
567 |
|
|
$ |
571 |
|
|
(1 |
)% |
|
|
(14 |
)% |
|
|
13 |
% |
| Australia |
|
|
35 |
|
|
28 |
|
|
25 |
% |
|
|
(13 |
)% |
|
|
38 |
% |
| Brazil |
|
|
46 |
|
|
64 |
|
|
(28 |
)% |
|
|
(36 |
)% |
|
|
8 |
% |
| Canada |
|
|
33 |
|
|
33 |
|
|
— |
% |
|
|
(14 |
)% |
|
|
14 |
% |
| China |
|
|
38 |
|
|
35 |
|
|
9 |
% |
|
|
(5 |
)% |
|
|
14 |
% |
| France |
|
|
36 |
|
|
26 |
|
|
38 |
% |
|
|
(8 |
)% |
|
|
46 |
% |
| Germany |
|
|
29 |
|
|
28 |
|
|
4 |
% |
|
|
(9 |
)% |
|
|
13 |
% |
| Italy |
|
|
20 |
|
|
25 |
|
|
(20 |
)% |
|
|
(8 |
)% |
|
|
(12 |
)% |
| Japan |
|
|
31 |
|
|
26 |
|
|
19 |
% |
|
|
1 |
% |
|
|
18 |
% |
| Mexico |
|
|
19 |
|
|
18 |
|
|
6 |
% |
|
|
(24 |
)% |
|
|
30 |
% |
| Spain |
|
|
19 |
|
|
19 |
|
|
— |
% |
|
|
(8 |
)% |
|
|
8 |
% |
| United Kingdom |
|
|
50 |
|
|
42 |
|
|
19 |
% |
|
|
(5 |
)% |
|
|
24 |
% |
| Other Developed |
|
|
68 |
|
|
65 |
|
|
5 |
% |
|
|
(8 |
)% |
|
|
13 |
% |
| Other Emerging |
|
|
143 |
|
|
162 |
|
|
(12 |
)% |
|
|
(13 |
)% |
|
|
1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certain amounts and percentages may reflect rounding adjustments.
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
ZOETIS INC.
SEGMENT(a) EARNINGS
(UNAUDITED)
(millions of dollars)
|
| |
|
|
|
First Quarter |
|
|
% Change |
|
|
|
2016 |
|
|
2015 |
|
|
Total |
|
|
Foreign
Exchange
|
|
|
Operational |
|
U.S.:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
$ |
582 |
|
|
|
$ |
521 |
|
|
|
12 |
% |
|
|
— |
% |
|
|
12 |
% |
| Cost of Sales |
|
|
131 |
|
|
|
125 |
|
|
|
5 |
% |
|
|
— |
% |
|
|
5 |
% |
| Gross Profit |
|
|
451 |
|
|
|
396 |
|
|
|
14 |
% |
|
|
— |
% |
|
|
14 |
% |
| Gross Margin |
|
|
77.5 |
% |
|
|
76.0 |
% |
|
|
|
|
|
|
|
|
|
| Operating Expenses |
|
|
92 |
|
|
|
81 |
|
|
|
14 |
% |
|
|
— |
% |
|
|
14 |
% |
| Other (income)/deductions |
|
|
— |
|
|
|
— |
|
|
|
— |
% |
|
|
— |
% |
|
|
— |
% |
| U.S. Earnings |
|
|
$ |
359 |
|
|
|
$ |
315 |
|
|
|
14 |
% |
|
|
— |
% |
|
|
14 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Revenue |
|
|
$ |
567 |
|
|
|
$ |
571 |
|
|
|
(1 |
)% |
|
|
(14 |
)% |
|
|
13 |
% |
| Cost of Sales |
|
|
196 |
|
|
|
204 |
|
|
|
(4 |
)% |
|
|
(13 |
)% |
|
|
9 |
% |
| Gross Profit |
|
|
371 |
|
|
|
367 |
|
|
|
1 |
% |
|
|
(13 |
)% |
|
|
14 |
% |
| Gross Margin |
|
|
65.4 |
% |
|
|
64.3 |
% |
|
|
|
|
|
|
|
|
|
| Operating Expenses |
|
|
109 |
|
|
|
135 |
|
|
|
(19 |
)% |
|
|
(11 |
)% |
|
|
(8 |
)% |
| Other (income)/deductions |
|
|
2 |
|
|
|
2 |
|
|
|
— |
% |
|
|
(19 |
)% |
|
|
19 |
% |
| International Earnings |
|
|
$ |
260 |
|
|
|
$ |
230 |
|
|
|
13 |
% |
|
|
(15 |
)% |
|
|
28 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Reportable Segments |
|
|
$ |
619 |
|
|
|
$ |
545 |
|
|
|
14 |
% |
|
|
(6 |
)% |
|
|
20 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Other business activities(b) |
|
|
(74 |
) |
|
|
(68 |
) |
|
|
9 |
% |
|
|
|
|
|
|
| Reconciling Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Corporate(c) |
|
|
(169 |
) |
|
|
(131 |
) |
|
|
29 |
% |
|
|
|
|
|
|
| Purchase accounting adjustments(d) |
|
|
(26 |
) |
|
|
(13 |
) |
|
|
100 |
% |
|
|
|
|
|
|
| Acquisition-related costs(e) |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
— |
% |
|
|
|
|
|
|
| Certain significant items(f) |
|
|
13 |
|
|
|
(41 |
) |
|
|
* |
|
|
|
|
|
|
| Other unallocated(g) |
|
|
(30 |
) |
|
|
(61 |
) |
|
|
(51 |
)% |
|
|
|
|
|
|
| Total Earnings(h) |
|
|
$ |
332 |
|
|
|
$ |
230 |
|
|
|
44 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * Calculation not meaningful. |
| |
| (a) |
|
For a description of each segment, see Note 19A to Zoetis' consolidated financial
statements included in Zoetis' Form 10-K for the year ended December 31, 2015. |
|
|
|
| (b) |
|
Other business activities reflect the research and development costs managed by our
Research and Development organization as well as our contract manufacturing business. |
|
|
|
| (c) |
|
Corporate includes, among other things, administration expenses, interest expense,
certain compensation and other costs not charged to our operating segments. |
|
|
|
| (d) |
|
Purchase accounting adjustments include certain charges related to the amortization
of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating
segments. |
|
|
|
| (e) |
|
Acquisition-related costs can include costs associated with acquiring and integrating
newly acquired businesses, such as transaction costs and integration costs. |
|
|
|
| (f) |
|
Certain significant items includes substantive, unusual items that, either as a
result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items
primarily include certain costs related to becoming an independent public company, restructuring charges and implementation
costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, costs associated
with the operational efficiency initiative and supply network strategy, certain legal and commercial settlements, and the
impact of divestiture-related gains and losses. |
|
|
|
| (g) |
|
Includes overhead expenses associated with our manufacturing and supply operations
not directly attributable to an operating segment, as well as procurement costs. |
|
|
|
| (h) |
|
Defined as income before provision for taxes on income. |
|
|
|
| Certain amounts and percentages may reflect rounding adjustments. |
| |
Zoetis Inc.
Media:
Bill Price, 1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investors:
John O'Connor, 1-973-822-7088 (o)
john.oconnor@zoetis.com
or
Steve Frank, 1-973-822-7141 (o)
steve.frank@zoetis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005928/en/